[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fuzhou General Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":194},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,39,66,93,115,136,154,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100628229","early-phase-1-therapy-for-advanced-nsclc-with-egfr-19delins-mutation-100628229",false,"NCT07458919","Therapy for Advanced NSCLC With EGFR 19delins Mutation","A Comparative Study on the Efficacy of First-generation Versus Third-generation EGFR TKIs as First-line Therapy for Advanced NSCLC With EGFR Exon 19 Deletion-insertion (19delins) Mutation","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer (NSCLC) (AJCC Cancer Staging Manual, 9th edition, Stage IIIB, IIIC or IV) that is not amenable or suitable for surgical resection or other radical therapies, as assessed by the investigator;\n* Epidermal growth factor receptor (EGFR) exon 19 deletion-insertion mutation (19delins) documented by testing of tumor tissue or plasma samples using methods including IHC, NGS, ARMS, etc.;\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1;\n* No prior systemic anti-tumor therapy for locally advanced or metastatic NSCLC;\n* Life expectancy ≥ 12 months;\n* At least one measurable lesion by imaging in the screening period according to RECIST v1.1;\n* Ability to swallow and retain oral medication;\n* Adequate organ system function;\n* Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to initiation of study treatment, and agree to use a medically accepted highly effective method of contraception during the study and for 3 months after the last dose of study drug;\n* Voluntary and able to comply with study and follow-up procedures; Ability to understand the nature of the trial and provide written informed consent.\n\nExclusion Criteria:\n\n* Advanced and\u002For symptomatic brain metastases (measurable or non-measurable) and\u002For leptomeningeal metastases;\n* Active hepatitis B, positive for hepatitis C virus antibody, positive for human immunodeficiency virus (HIV) antibody, or positive for Treponema pallidum antibody;\n* Women of childbearing potential with a positive serum pregnancy test within 7 days prior to initiation of treatment, pregnant or lactating women, or male and female subjects who are not using effective contraception or plan to conceive during the entire treatment period and for 3 months after the end of treatment;\n* Patients who have used any of the following medications within 14 days prior to the first dose or require concomitant use of such medications during treatment: drugs with a risk of causing QTc prolongation and\u002For torsade de pointes; strong inhibitors or strong inducers of CYP3A;\n* Underwent major surgery or immunotherapy within 4 weeks prior to the first dose; received radiation therapy within 2 weeks prior to the first dose;\n* Patients with imaging evidence of tumor invasion of major blood vessels, or those judged to have a very high likelihood of tumor invasion of critical blood vessels leading to fatal massive hemorrhage during the subsequent study period;\n* History of interstitial lung disease, drug-induced interstitial disease, or any clinically evident active interstitial lung disease; presence of idiopathic pulmonary fibrosis on baseline CT scan;\n* Other severe, acute, or chronic medical conditions that, in the investigator's opinion, may increase the risk associated with study participation or may interfere with the interpretation of study results, including uncontrolled diabetes mellitus, medical or psychiatric illnesses, or laboratory abnormalities;\n* Any other conditions deemed by the investigator to make the subject unsuitable for participation in this trial.","ALL","18 Years",{"count":19,"type":20},94,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","In a retrospective analysis of 3,054 advanced NSCLC patients, 41 with EGFR exon 19 deletion-insertions (19delins) received first-generation EGFR TKIs, achieving median PFS of 10.4 months; those with L747\\_T751delinsP had notably longer PFS of 18.7 months. Another study of 2,467 treatment-naïve patients found 93 with 19delins treated with first-generation TKIs had median PFS of 19 months, exceeding the 13 months for common 19del mutations. For third-generation TKIs, a study of 215 19delins patients (57 first-line) showed median PFS of 12.9 months, inferior to 23.2 months for common 19del. Our center's retrospective study of 4,666 NSCLC patients in Fujian (2017-2020) included 69 with 19delins: median PFS was 16.7 months with first-generation TKIs versus 7.2 months with third-generation. Evidence suggests specific EGFR deletion locations may affect TKI efficacy; first-generation TKIs may be superior in some 19delins subtypes, while third-generation appear limited. Large prospective data are lacking. This project aims to compare first- versus third-generation EGFR TKIs in 19delins patients via a randomized controlled trial, stratify sensitivity by subtype, and improve survival.",[26],"Lung Cancer","NOT_YET_RECRUITING","2026-03-04",{"date":30,"type":31},"2026-03-09","ACTUAL",{"date":33,"type":20},"2026-03-30",{"date":35,"type":20},"2030-10-30",{"name":37,"class":38},"Fuzhou General Hospital","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100600151","efficacy-and-safety-analysis-of-first-line-abcp-therapy-in-advanced-smarca4-mutated-nsclc-100600151","NCT07093762","Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC","Efficacy and Safety Analysis of First-Line ABCP Four-Drug Combination Therapy in Advanced SMARCA4-Mutated Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Prespecified Subgroup Clinical Trial","Inclusion Criteria:\n\n1. Patients with pathologically confirmed NSCLC, meeting the following criteria based on the IASLC 9th Edition Lung Cancer TNM Staging System (International Association for the Study of Lung Cancer\u002FUnion for International Cancer Control): Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB\u002FIIIC) disease not amenable to curative-intent concurrent chemoradiotherapy, metastatic, or recurrent (Stage IV) non-squamous NSCLC;\n2. Confirmed SMARCA4 mutation (verified by NGS testing);\n3. ECOG performance status 0-1, with no prior systemic anticancer therapy;\n4. Absence of driver gene mutations (e.g., EGFR, ALK, ROS1);\n5. Patients capable of providing sufficient blood samples (detailed in sample requirements) and complete baseline clinical data, including: age, gender, smoking history, family history, lesion location(s), lesion size(s), number of lesions, tumor markers, pathological indicators, treatment records, and re-examination\u002Ffollow-up information;\n6. Voluntary participation with signed informed consent form, willingness to undergo follow-up assessments and provide treatment process details, efficacy data, and prognostic information, with commitment to complete the entire study.\n\nExclusion Criteria:\n\n* (1) Active autoimmune diseases or interstitial lung disease; (2) Bleeding tendency or contraindications to Bevacizumab.",{"count":47,"type":20},35,"OBSERVATIONAL","SMARCA4 mutation is clinically known to be an independent poor prognostic factor. Both TCGA and the investigators institution's preliminary research indicate that the median overall survival (OS) of mutated patients is significantly shorter than that of wild-type patients (32 months vs. 157.7 months, respectively, P=0.001); it is associated with chemotherapy\u002Fimmunotherapy resistance, rapid progression, and poor prognosis (OS\\\u003C12 months). Current standard first-line treatments (such as platinum-based chemotherapy ± immunotherapy) have limited efficacy in SMARCA4-mutated patients (ORR\\\u003C30%, PFS\\\u003C4 months). Additionally, NapsinA-positive expression can improve the survival of mutated patients (median OS: 32 months vs. 15 months, P=0.033), but this effect exists only in the SMARCA4-mutated group.\n\nThe ABCP regimen has a synergistic mechanism: Atezolizumab (anti-PD-L1): reverses the immunosuppressive microenvironment; Bevacizumab (anti-VEGF): inhibits angiogenesis and enhances T-cell infiltration; Platinum + Paclitaxel: directly kill tumor cells and release neoantigens. Therefore, the investigators preset that SMARCA4 mutation may affect chemotherapy\u002Fimmunotherapy response through epigenetic regulation, and its value as a predictive biomarker needs to be validated. Hence, the purpose of this study is to observe and explore the efficacy and safety of first-line ABCP four-drug combination therapy in patients with advanced SMARCA4-mutated non-small cell lung cancer.",[51],"Non Small Cell Lung Cancer",[53,54,55,56],"SMARCA4","NSCLC","treatment efficacy","biomarker","2025-07-22",{"date":59,"type":31},"2025-07-30",{"date":61,"type":20},"2025-08-20",{"date":63,"type":20},"2028-06-30",{"name":37,"class":38},1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":75,"studyType":48,"phases":4,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100575647","sers-based-serum-molecular-spectral-screening-for-lung-cancer-type-100575647","NCT06775002","SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type","SERS-Based Serum Molecular Spectral Screening for Non-Small Cell Lung Cancer vs. Small Cell Lung Cancer: A Multicenter, Open-Label, Double-Blind, Independent Data Analysis Clinical Trial","Inclusion Criteria:\n\n1. Participants with Lung cancer meeting the criteria of TNM (Ninth Edition);\n2. Participants are willing to participate in this study and follow the research plan;\n3. Participants or legally authorized representatives can give written informed consent approved by the Ethics Review Committee that manages the website;.\n\nExclusion Criteria:\n\n1. Participants with concomitant other malignant tumors;\n2. Participants with missing baseline clinical data;\n3. Participants with severe underlying pulmonary diseases (such as bronchiectasis, bronchial asthma, or COPD), or those with a history of occupational or environmental exposure to dust, mines, or asbestos;\n4. Participants who are uncooperative or refuse to participate in the clinical trial later on.",{"count":74,"type":20},223,"1 Year","Lung cancer can be divided into two major categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for about 85% and SCLC about 15%. The prognoses of different types of lung cancer vary significantly. Early identification of different pathological types of lung cancer is crucial to the patient's prognosis.\n\nRaman Spectrum (RS), as a non-invasive and highly specific molecular detection technique, can obtain information at the molecular level, thereby sensitively detecting changes in biomolecules related to tumor metabolism such as proteins, nucleic acids, lipids, and sugars. Surface-enhanced Raman spectroscopy (SERS), developed based on this technology, is one of the feasible methods for high-sensitivity biomolecular analysis.\n\nIn preliminary study, the investigators collected serum Raman spectral data from a cohort of 233 patients with malignant lung tumors and built a Raman intelligent diagnostic system for SCLC and NSCLC based on a machine learning model, achieving an accuracy rate of 80%. To obtain the highest level of clinical evidence and truly achieve clinical translation, this prospective, multicenter clinical study aims to validate the use of this intelligent diagnostic system for the early diagnosis of SCLC.",[78,79],"Lung Cancer, Non-Small Cell","Lung Cancer Small Cell Lung Cancer (SCLC)",[81,82,54,83,84],"SERS","Raman","SCLC","diagnostic model","2025-03-26",{"date":87,"type":31},"2025-03-31",{"date":89,"type":20},"2026-04-05",{"date":91,"type":20},"2026-11-20",{"name":37,"class":38},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":75,"studyType":48,"phases":4,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":4},"100575445","sers-sensor-based-on-cha-reaction-for-egfr-mutation-typing-in-advanced-lung-cancer-100575445","NCT06772376","SERS Sensor Based on CHA Reaction for EGFR Mutation Typing in Advanced Lung Cancer","SERS Sensor Based on CHA Reaction for EGFR Mutation Typing in Advanced Lung Cancer: A Multicenter, Open-Label, Double-Blind, Independent Data Analysis Clinical Trial","Inclusion Criteria:\n\n1. Participants with Lung cancer meeting the criteria of TNM (Ninth Edition);\n2. Participants are willing to participate in this study and follow the research plan;\n3. Participants or legally authorized representatives can give written informed consent approved by the Ethics Review Committee that manages the website;\n\nExclusion Criteria:\n\n1. Patients with other active malignant tumors;\n2. Patients with missing baseline clinical data;\n3. Patients with severe underlying lung diseases (such as bronchiectasis, bronchial asthma or COPD, etc.), or those with a history of occupational or environmental exposure to dust, mines or asbestos;\n4. Participants who do not cooperate or refuse to participate in clinical trials at a later stage.",{"count":101,"type":20},400,"Summary:This study is a prospective, multicenter clinical study. In previous studies, we successfully constructed a CHA reaction-mediated self-calibrated SERS biosensor for the detection of EGFR mutation typing (Del-19, T790M, L858R) in lung cancer patients, and verified that the accuracy, sensitivity, and specificity of the SERS biosensor exceeded 95% in a small sample of 32 patients. In order to obtain the highest level of clinical evidence and truly achieve clinical transformation, this prospective, multicenter clinical study aims to verify the analytical efficiency of the SERS biosensor for EGFR mutation typing in patients with advanced lung cancer.\n\nPurpose：This prospective, multicenter clinical study aims to verify the analytical efficacy of the previously constructed CHA reaction-mediated self-calibrated SERS biosensor in EGFR mutation typing in patients with advanced lung cancer.\n\nResearch subjects: The patients enrolled in this project are confirmed to be advanced non-small cell lung cancer (NSCLC). Enrollment will be completed in 25 centers and the enrollment will be competitive.\n\nResearch location: 900th Hospital of Joint Logistics Support Force Research intervention: None Study duration: Patients will be enrolled from June 2024 to June 2025. Subject participation time: Telephone follow-up will be conducted every three months until the end of the study.",[104],"Lung Cancer in Normal and Malignant Tumors",[81,106,107,108],"CHA","EGFR","advanced lung cancer",{"date":87,"type":31},{"date":111,"type":20},"2026-05-01",{"date":113,"type":20},"2026-06-01",{"name":37,"class":38},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":75,"studyType":48,"phases":4,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":65},"100575692","sers-based-serum-molecular-spectral-screening-for-benign-and-malignant-pulmonary-proliferative-nodules-100575692","NCT06775587","SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules","SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules: A Multicenter, Open-Label, Double-Blind, Independent Data Analysis Clinical Trial","SERS on lung","Inclusion Criteria:\n\n1. Participants with Lung cancer meeting the criteria of TNM (Ninth Edition);\n2. Participants are willing to participate in this study and follow the research plan;\n3. Participants or legally authorized representatives can give written informed consent approved by the Ethics Review Committee that manages the website.\n\nExclusion Criteria:\n\n1. Participants with concomitant other malignant tumors;\n2. Participants with missing baseline clinical data;\n3. Participants with severe underlying lung diseases (such as bronchiectasis, bronchial asthma or COPD, etc.), or those with a history of occupational or environmental exposure to dust, mines or asbestos;\n4. Participants who do not cooperate or refuse to participate in clinical trials at a later stage.",{"count":124,"type":20},200,"Pulmonary nodules are often an early indicator of lung cancer. With the widespread adoption of chest CT scans in routine physical examinations, an increasing number of pulmonary nodules are being detected, including a variety of small nodules such as inflammatory lesions, benign tumors, and malignant tumors. Currently, there is no unified international consensus on the diagnostic and treatment strategies for pulmonary nodules, as outlined by various global guidelines. Developing and implementing a comprehensive lung nodule and lung cancer screening program within public health management systems remains a complex and challenging endeavor. Advancing research and proposing lung cancer screening technologies that are highly sensitive, highly specific, simple, accessible, and cost-effective is an essential and pressing priority in modern healthcare.\n\nRaman spectroscopy (RS), as a non-invasive and highly specific molecular detection technique, can be obtained at the molecular level to sensitively detect changes in biomolecules composed of proteins, nucleic acids, lipids, and sugars related to tumor metabolism in biological samples. The surface enhanced Raman spectroscopy (SERS) developed based on this technology is one of the feasible methods for high-sensitivity biomolecule analysis. Although SERS technology has shown good diagnostic efficacy in lots of preclinical studies in multiple tumors, it is limited to a generally small sample size and lacks external validation. There for, a clinical study of Raman spectra for tumor diagnosis is needed, which meets the following requirements: 1.An objective, fast and practical application of Raman spectral data processing is needed and deep learning method may be the best classification method; 2. It requires multicenter and large clinical samples to train deep learning diagnostic model, and verify its true efficacy through external data of prospective study.\n\nIn preliminary research, the investigators collected serum Raman spectroscopy data from a cohort of 191 patients with pulmonary nodules and developed an intelligent diagnosis system for distinguishing between benign and malignant pulmonary nodules using a machine learning model. The system achieved an accuracy of 89.7%. In order to obtain the highest level of clinical evidence and truly realize clinical transformation, this prospective, multi-center clinical study is designed to verify the intelligent diagnostic system for early diagnosis of prostate cancer.",[104],[81,82,128,129,84],"Early screening for lung cancer","Pulmonary nodule",{"date":87,"type":31},{"date":132,"type":20},"2026-04-08",{"date":134,"type":20},"2026-12-31",{"name":37,"class":38},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":75,"studyType":48,"phases":4,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":65},"100575648","sers-based-serum-molecular-spectral-detection-of-invasive-lung-cancer-100575648","NCT06775015","SERS-Based Serum Molecular Spectral Detection of Invasive Lung Cancer","SERS-Based Serum Molecular Spectral Detection of Lung Cancer Microinvasion Versus Invasion Screening: A Multicenter, Open-Label, Double-Blind, Independent Data Analysis Clinical Trial","Inclusion Criteria:\n\n1. Participants confirmed by chest CT to have pulmonary nodules\n2. The diagnosis of participants with malignant pulmonary nodules must meet the TNM diagnostic criteria (Ninth Edition);\n3. Participants are willing to participate in this study and follow the research plan;\n4. Participants or legally authorized representatives can give written informed consent approved by the Ethics Review Committee that manages the website;\n\nExclusion Criteria:\n\n1. Participants with concomitant other malignant tumors;\n2. Participants with missing baseline clinical data;\n3. Participants with severe underlying lung diseases (such as bronchiectasis, bronchial asthma or COPD, etc.), or those with a history of occupational or environmental exposure to dust, mines or asbestos;\n4. Participants who do not cooperate or refuse to participate in clinical trials at a later stage.",{"count":124,"type":20},"Surgery is the main treatment for early lung cancer. It is worth noting that there are significant differences in postoperative prognosis and surgical methods between microinvasive cancer and early-stage invasive cancer. Micro invasive lung cancer can achieve 100% long-term survival through surgical resection, without the need for postoperative adjuvant radiotherapy. There is no need to remove lung lobes during surgery, only segmental or wedge resection is required, and systematic lymph node dissection is not recommended. Therefore, accurate prediction of preoperative and intraoperative microinvasive cancer and invasive cancer in pulmonary nodules is crucial for patients to choose surgical methods, which can significantly affect postoperative lung function retention and overall survival.\n\nRaman spectroscopy (RS), as a non-invasive and highly specific molecular detection technique, can be obtained at the molecular level to sensitively detect changes in biomolecules composed of proteins, nucleic acids, lipids, and sugars related to tumor metabolism in biological samples. The surface enhanced Raman spectroscopy (SERS) developed based on this technology is one of the feasible methods for high-sensitivity biomolecule analysis.\n\nWe collected serum Raman spectroscopy data from a cohort of 138 early lung cancer patients in our preliminary research. Based on a machine learning model, we constructed an early lung microinvasive cancer and invasive cancer Raman intelligent diagnosis system, which achieved an accuracy rate of 89.4%. To obtain the highest level of clinical evidence and truly achieve clinical translation, this prospective, multicenter clinical study aims to validate the use of this intelligent diagnostic system for early diagnosis of lung cancer and the discrimination between microinvasive cancer and invasive cancer.",[146],"Lung Cancer Patients",[148],"SERS，Raman，Early screening for lung cancer，Pulmonary nodule，diagnostic model",{"date":87,"type":31},{"date":151,"type":20},"2026-04-04",{"date":134,"type":20},{"name":37,"class":38},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":170,"locationsCount":65},"100575444","sers-based-serum-molecular-spectral-screening-for-hematogenous-metastasis-100575444","NCT06772363","SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis","SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis vs. Non-Metastasis in Non-Small Cell Lung Cancer: A Multicenter, Open-Label, Double-Blind, Independent Data Analysis Clinical Trial","Inclusion Criteria:\n\n1. Participants with Lung cancer meeting the criteria of TNM (Ninth Edition);\n2. Participants are willing to participate in this study and follow the research plan;\n3. Participants or legally authorized representatives can give written informed consent approved by the Ethics Review Committee that manages the website;\n\nExclusion Criteria:\n\n1. Participants with concomitant other malignant tumors;\n2. Participants with missing baseline clinical data;\n3. Participants with severe underlying lung diseases (such as bronchiectasis, bronchial asthma or COPD, etc.), or those with a history of occupational or environmental exposure to dust, mines or asbestos;\n4. Participants who do not cooperate or refuse to participate in clinical trials at a later stage.",{"count":124,"type":20},"Although modern medicine has made significant progress in the diagnosis and treatment of lung cancer, most patients are diagnosed at locally advanced stage or with distant metastases, especially in the late stages where the cancer has spread to other organs through hematogenous metastasis. This not only significantly the survival rate of patients but also increases the complexity and difficulty of treatment. Hematogenous metastasis plays an important role in the clinical progression of lung cancer, its complex biological processes pose a huge challenge for clinical management. Early detection of hematogenous metastasis is difficult, and traditional imaging methods have limited sensitivity in detecting small metastatic lesions. The emerging technology of circulating tumor cells (CTCs) has been limited in clinical application due to its high detection costs and technical requirements. Therefore researching and developing high-sensitivity, high-specificity, simple, easy-to-popularize, and low-cost technologies to predict the risk of hematogenous metastasis lung cancer is crucial for early diagnosis and more precise treatment. Raman spectroscopy (RS), a non-invasive and highly specific molecular detection technology, can detect in biomolecules such as proteins, nucleic acids, lipids, and sugars related to tumor metabolism in biological samples at the molecular level. Surface-enhanced R spectroscopy (SERS), developed based on this technology, is one of the feasible methods for high-sensitivity biomolecular analysis. Although SERS technology has shown diagnostic results in numerous preclinical studies of various tumors, it is limited by small sample sizes and lacks external validation. Therefore, clinical studies on the diagnosis of tumors Raman spectroscopy are needed, with the following requirements: 1. Objective, rapid, and practical Raman spectroscopy data processing methods are needed, and and deep learning methods may be the best classification methods; 2. Multicenter, large-sample clinical samples are needed to train deep learning diagnostic models, and real-world performance should be validated through external data from prospective studies. In previous study, the investigators collected serum Raman spectroscopy data from a cohort of 23 patients with lung malignancies and developed an intelligent Raman diagnostic system for hematogenous metastasis in non-small cell lung cancer (NSCLC) based on learning models, with an accuracy rate of 95%. To obtain the highest level of clinical evidence and truly achieve clinical translation, this prospective, multicenter clinical aims to validate the use of this intelligent diagnostic system for early diagnosis of hematogenous metastasis in NSCLC.",[164],"Lung Cancers",[81,54,82,84],{"date":87,"type":31},{"date":168,"type":20},"2026-04-09",{"date":113,"type":20},{"name":37,"class":38},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":65},"100478848","phase-2-induction-tislelizumab-combined-with-chemotherapy-followed-by-definitive-chemoradiotherapy-in-the-treatment-of-locally-unresectable-esophageal-squamous-cell-carcinoma-100478848","NCT05515315","Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Histologically confirmed localized ESCC that is suitable for cCRT, including: stage II-IVA (AJCC version 8) inoperable ESCC (medically unfit for surgery or refusing surgical intervention);;\n* Aged 18-70, both sexes;\n* ECOG score 0-1\n* The presence of measurable and\u002For nonmeasurable lesions that met the definition of RECIST1.1;\n* Adequate organ and bone marrow function, meeting the following definitions:\n\n  1. Blood routine (no blood transfusion, no granulocyte colony-stimulating factor \\[G-CSF\\], and no other drugs were used within 14 days before treatment);Absolute neutrophil count (ANC) ≥1.5×109\u002FL;Hemoglobin (HB) ≥9.0 g\u002FdL;Platelet count (PLT) ≥100×109\u002FL;\n  2. Blood biochemistry Creatinine clearance rate ≥60 mL\u002Fmin;Total bilirubin (TBIL) ≤ 1.5×ULN;Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤2.5×ULN;\n* Expected survival time \\> 6 months;\n* Fertile female subjects and male subjects with partners of reproductive age are required to use a medically approved contraceptive method during the study treatment period and for at least 3 months after the last treatment;\n* Patients who volunteered to participate in this study and signed the informed consent form.\n\nExclusion Criteria:\n\n* A history of fistula caused by primary tumor invasion;\n* Presence of clinically uncontrolled pleural effusion, pericardial effusion, or ascites that required repeated drainage or medical intervention (within 2 weeks before randomization);\n* Known intolerance or resistance to chemotherapy specified in the trial protocol;\n* have received any other ESCC antitumor therapy (e.g., therapy targeting PD-1, PD-L1, PD-L2 or other tumor immunotherapy, radiotherapy, targeted therapy, ablation or other systemic or local antitumor therapy);\n* Patients with active autoimmune disease or a history of autoimmune disease that may relapse, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* History of interstitial lung disease, non-infectious pneumonia or uncontrolled systemic diseases, including pulmonary fibrosis and acute lung disease;\n* Severe chronic or active infection (including tuberculosis infection) requiring systemic antimicrobial therapy, antifungal therapy or antiviral therapy before enrollment;\n* Known history of HIV infection;\n* Other malignancies (except cured basal cell carcinoma of the skin, carcinoma in situ of the breast and carcinoma in situ of the cervix) in the past 5 years;\n* Received live vaccine within 28 days before enrollment;\n* while participating in another therapeutic clinical trial.","70 Years",{"count":179,"type":20},93,[181],"PHASE2","To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)",[184],"Immunotherapy Esophagus Cancer","RECRUITING","2024-02-04",{"date":188,"type":31},"2024-02-07",{"date":190,"type":31},"2022-05-31",{"date":192,"type":20},"2027-05-31",{"name":37,"class":38},""]